CN Patent

CN108135177B — 用于治疗癌症的方法

Assigned to Radius Pharmaceuticals Inc · Expires 2021-06-01 · 5y expired

What this patent protects

本文公开了在具有耐药性雌激素受体α阳性癌症或突变型雌激素受体α阳性癌症的受试者中抑制肿瘤生长或产生肿瘤消退的方法。该方法需要向受试者施用治疗有效量的、具有以下结构的RAD1901或其盐或其溶剂化物：

USPTO Abstract

本文公开了在具有耐药性雌激素受体α阳性癌症或突变型雌激素受体α阳性癌症的受试者中抑制肿瘤生长或产生肿瘤消退的方法。该方法需要向受试者施用治疗有效量的、具有以下结构的RAD1901或其盐或其溶剂化物：

Drugs covered by this patent

elacestrant-hydrochloride (ELACESTRANT HYDROCHLORIDE)

Patent Metadata

Patent number: CN108135177B
Jurisdiction: CN
Classification: —
Expires: 2021-06-01
Drug substance claim: No
Drug product claim: No
Assignee: Radius Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.